A trial of antithrombotic therapy in patients with refractory migraine and antiphospholipid antibodies: A retrospective study of 75 patients.
CONCLUSIONS: There was a high rate of symptomatic response to antithrombotic therapy in this context and long-term follow up suggested an individualized symptom-derived antithrombotic regimen may be associated with a low bleeding risk. Our data support consideration of a 2-4 week trial of antithrombotic therapy, usually starting with antiplatelet therapy, in aPL-positive patients with refractory migraine, particularly if other treatment options have been exhausted. As a retrospective study, our data provide only Class IV level of evidence, but they suggest randomized controlled trials are warranted to validate these encouraging findings.
PMID: 33402037 [PubMed - as supplied by publisher]
Source: Lupus - Category: Rheumatology Authors: Schofield JR, Hughes HN, Birlea M, Hassell KL Tags: Lupus Source Type: research
More News: Antiphospholipid Syndrome | Aspirin | Bleeding | Clopidogrel | Headache | Hughes Syndrome | Lupus | Migraine | Plavix | Rheumatology | Stroke | Study